Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

52.20 -0.08 (-0.15%)
Streaming Delayed Price Updated: 12:19 PM EDT, May 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 307,476
Open 52.92
Bid (Size) 52.12 (300)
Ask (Size) 52.27 (400)
Prev. Close 52.28
Today's Range 51.12 - 52.98
52wk Range 28.66 - 91.00
Shares Outstanding 115,926,629
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
3 High-Flying Stocks We Think Twice About
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ... 
Via StockStory
News headline image
Corcept (CORT) Q1 2026 Earnings Transcript ↗
Corcept (CORT) Q1 2026 Earnings Transcript 
Via The Motley Fool

Performance

YTD
+36.6%
+36.6%
1 Month
+24.6%
+24.6%
3 Month
+26.4%
+26.4%
6 Month
-30.9%
-30.9%
1 Year
-27.6%
-27.6%

More News

Read More
News headline image
Corcept (CORT) Q4 2025 Earnings Transcript ↗
Via The Motley Fool
Corcept Therapeutics (NASDAQ:CORT) Revenue Miss Leads to Q1 Net Loss, But Guidance Upgrade and Lifyorli Launch Signal Strong Momentum ↗
Via Chartmill
News headline image
Corcept (CORT) Q1 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
Corcept (CORT) Q2 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
CORT Q1 Deep Dive: Early Lifyorli Launch and Endocrinology Momentum Offset Margin Pressures
Via StockStory
News headline image
Corcept (NASDAQ:CORT) Misses Q1 CY2026 Revenue Estimates
Via StockStory
News headline image
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept Earnings: What To Look For From CORT
Via StockStory
Topics Artificial Intelligence
News headline image
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
CORCEPT DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class Action – CORT
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
1 Cash-Producing Stock for Long-Term Investors and 2 We Ignore
Via StockStory
News headline image
CORCEPT DEADLINE TOMORROW: Bragar Eagel & Squire, P.C. Urges Corcept Therapeutics Incorporated Investors to Contact the Firm Regarding Their Rights Before April 21st
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Revvity, Bio-Techne, Corcept, Supernus Pharmaceuticals, and Phibro Animal Health Shares Skyrocket, What You Need To Know
Via StockStory
Topics Economy
News headline image
Deadline Soon: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT
From SkyMedia, LLC
Via GlobeNewswire
News headline image
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
3 Overrated Stocks That Concern Us
Via StockStory
News headline image
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Corcept Therapeutics Incorporated and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Frequently Asked Questions

Is Corcept Therapeutics Incorporated - Common Stock publicly traded?
Yes, Corcept Therapeutics Incorporated - Common Stock is publicly traded.
What exchange does Corcept Therapeutics Incorporated - Common Stock trade on?
Corcept Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Corcept Therapeutics Incorporated - Common Stock?
The ticker symbol for Corcept Therapeutics Incorporated - Common Stock is CORT on the Nasdaq Stock Market
What is the current price of Corcept Therapeutics Incorporated - Common Stock?
The current price of Corcept Therapeutics Incorporated - Common Stock is 52.20
When was Corcept Therapeutics Incorporated - Common Stock last traded?
The last trade of Corcept Therapeutics Incorporated - Common Stock was at 05/11/26 12:19 PM ET
What is the market capitalization of Corcept Therapeutics Incorporated - Common Stock?
The market capitalization of Corcept Therapeutics Incorporated - Common Stock is 6.05B
How many shares of Corcept Therapeutics Incorporated - Common Stock are outstanding?
Corcept Therapeutics Incorporated - Common Stock has 6B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.